All In Biotech

Drug Trial Radar · NCT02879578

Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects With Tourette Syndrome

Last checked: Nov 20, 2026Latest source record: Apr 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

155

Actual

Start

Jul 25, 2016

Primary completion

Nov 1, 2017

Study completion Nov 1, 2017

Sponsor

Lead sponsor
Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
Sponsor type
Industry
First posted
Aug 25, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 6 years, up to 64 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Phase 2, open-label, fixed-dose titration study to evaluate the safety and tolerability of NBI-98854 administered once daily for a total of 24 weeks in children, adolescents, and adults with Tourette Syndrome (TS).

Conditions

  • Tourette Syndrome

Interventions

  • ValbenazineDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Frequency of Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline through Week 28

Locations

13 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Sun City, Arizona

  • Site not named

    San Diego, California

  • Site not named

    Loxahatchee Groves, Florida

  • Site not named

    St. Petersburg, Florida

  • Site not named

    Tampa, Florida

  • Site not named

    Naperville, Illinois

  • Site not named

    Lincoln, Nebraska

  • Site not named

    Summit, New Jersey

  • Site not named

    New York, New York

  • Site not named

    Norristown, Pennsylvania

  • Site not named

    Nashville, Tennessee

  • Site not named

    Fort Worth, Texas

  • Site not named

    Spokane, Washington

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.